Inventor
LI ZONGHAI
CN17 patents
⚠️ This page may combine multiple inventors who share the name “LI ZONGHAI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CRAGE MEDICAL CO LTD
9 patentsUS11447570B2Sep 20, 2022
Binding unit targeting fibroblast activation protein α and application thereof
CRAGE MEDICAL CO LTD2 citations72
US12435119B2Oct 7, 2025
Genetically engineered cell and application thereof
CRAGE MEDICAL CO LTD0 citations62
US11419895B2Aug 23, 2022
Compositions and methods of cellular immunotherapy
CRAGE MEDICAL CO LTD0 citations62
US12534532B2Jan 27, 2026
CLL1-targeting antibody and application thereof
CRAGE MEDICAL CO LTD0 citations61
US12186343B2Jan 7, 2025
Method and composition for treating tumors
CRAGE MEDICAL CO LTD0 citations61
US11596653B2Mar 7, 2023
Compositions and methods of cellular immunotherapy
CRAGE MEDICAL CO LTD0 citations61
US11299525B2Apr 12, 2022
Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent
CRAGE MEDICAL CO LTD0 citations58
US11427633B2Aug 30, 2022
Anti-CD19 humanized antibody and immune effector cell targeting cd 19
CRAGE MEDICAL CO LTD0 citations50
US12178786B2Dec 31, 2024
Combination of cellular immunotherapy
CRAGE MEDICAL CO LTD0 citations44
LI ZONGHAI
3 patentsUS8506963B2Aug 13, 2013
Anti-EFGRv3 monoclonal antibody
LI ZONGHAI16 citations81
US8796421B2Aug 5, 2014
Human epidermal growth factor receptor variant lacking an exon
LI ZONGHAI3 citations60
US8703917B2Apr 22, 2014
Epidermal growth factor receptor variants and pharmaceutical compositions thereof
LI ZONGHAI3 citations57
CARSGEN THERAPEUTICS LTD
2 patentsUS10604740B2Mar 31, 2020
Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
CARSGEN THERAPEUTICS LTD5 citations69
US10731127B2Aug 4, 2020
Chimeric antigen receptors targeting GPC3 and uses thereof
CARSGEN THERAPEUTICS LTD3 citations68